Cargando…
Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916315/ https://www.ncbi.nlm.nih.gov/pubmed/24495546 http://dx.doi.org/10.1186/1480-9222-16-3 |
_version_ | 1782302691683205120 |
---|---|
author | Hu, Jiemiao Vien, Long T Xia, Xueqing Bover, Laura Li, Shulin |
author_facet | Hu, Jiemiao Vien, Long T Xia, Xueqing Bover, Laura Li, Shulin |
author_sort | Hu, Jiemiao |
collection | PubMed |
description | BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover, currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and costly. RESULTS: We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining. CONCLUSIONS: Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs. |
format | Online Article Text |
id | pubmed-3916315 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-39163152014-02-07 Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells Hu, Jiemiao Vien, Long T Xia, Xueqing Bover, Laura Li, Shulin Biol Proced Online Methodology BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover, currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and costly. RESULTS: We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining. CONCLUSIONS: Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs. BioMed Central 2014-02-04 /pmc/articles/PMC3916315/ /pubmed/24495546 http://dx.doi.org/10.1186/1480-9222-16-3 Text en Copyright © 2014 Hu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Methodology Hu, Jiemiao Vien, Long T Xia, Xueqing Bover, Laura Li, Shulin Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title | Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title_full | Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title_fullStr | Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title_full_unstemmed | Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title_short | Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells |
title_sort | generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein rae-1 using genetically engineered tumor cells |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916315/ https://www.ncbi.nlm.nih.gov/pubmed/24495546 http://dx.doi.org/10.1186/1480-9222-16-3 |
work_keys_str_mv | AT hujiemiao generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells AT vienlongt generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells AT xiaxueqing generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells AT boverlaura generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells AT lishulin generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells |